JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma
About this episode
Dr. Ash Gurumurthi and Dr. Grant McArthur discuss the latest findings on neoantigen therapy in melanoma from the ASCO 2026 conference.
JCO Editorial Fellow Dr. Ash Gurumurthi and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2026 Simultaneous Publication paper " Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study ." LINK TO FULL TRANSCRIPT
More episodes of Journal of Clinical Oncology (JCO) Podcast
- Effectiveness of a Virtual Tobacco Treatment for Cancer Patients
- Phase 2 Study of Multi-Cancer Detection from Breath Samples
- JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma
- JCO at ASCO 2026: Individual Patient Pooled Analysis of Low-Dose Tamoxifen in DCIS
- JCO at ASCO 2026: Neoadjuvant Sacituzumab in MIBC
- JCO at ASCO 2026: Intravesical Recombinant BCG with Chemo-Immunotherapy in MIBC
Explore listener stats, chart rankings, contacts and more on the Journal of Clinical Oncology (JCO) Podcast podcast page.